Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Edison Investment Research-Archiv vom 29.02.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
29.02.24Good Life Plus - Welcome to the Goodlife!133Good Life Plus (GL+) is an early-stage, entertainment-focused, subscription-based prize draw operator. Based in the UK, the business was founded in 2021. The majority of GL+'s members pay a subscription...
► Artikel lesen
29.02.24Nano Dimension - Share buyback underway359Nano Dimension has provided a business update that highlights a major R&D milestone, a system sale to a defence customer and the start of a $200m share buyback programme. Management is focused on optimising...
► Artikel lesen
29.02.24S&U - Impairments drag FY24 PBT, moderation in FY25284In its trading update between December 2023 and January 2024, S&U announced that FY24 PBT will be 10% to 15% below consensus of c £38m. The key reason is lower collection rates in Advantage of 90% (H123:...
► Artikel lesen
29.02.24The Law Debenture Corporation - One plus one equals three276FY23 results for The Law Debenture Corporation (LWDB) show this well-proven, rare combination of a UK investment trust and the cash-generative professional services operating business (IPS) continuing...
► Artikel lesen
29.02.24Freelancer - Primed for margin expansion289Freelancer's FY23 results marked a key milestone as the group moved to positive operating EBITDA. Profitability was driven by lower opex than we anticipated as gross marketplace volume (GMV) and revenue...
► Artikel lesen
29.02.24Actinogen Medical - Pressing forward with Xanamem336Having shown cognitive activity in prior trials, Actinogen began its XanaMIA Phase IIb study of lead candidate Xanamem in patients with cognitive impairment (CI) associated with mild-to-moderate Alzheimer's...
► Artikel lesen